"inhibitor"的词根是"hibit-",来源于拉丁语,意为“持有”或“保持”。在这个单词中,它引申为“阻止”或“抑制”。 后缀"-or"通常表示“做某事的人”或“某物”。在这里,它表示这是一种具有抑制作用的物质。 记忆辅助 你可以这样记忆这个单词:想象一个“持有”力量来“阻止”或“抑制”某种活动的物质,这就是...
These data provide evidence that inhibition of RANKL, in this case by its natural inhibitor OPG, can have clinically measurable effects. However, the development of OPG as a therapy for osteoporosis was not pursued because of its potential immunogenicity, because immunologic resistance to OPG could ...
Study on the correlation factors of total hip bone density change in postmenopausal osteoporosis patients treated with RANKL inhibitor desumab 在线阅读 下载PDF 引用 收藏 分享 摘要 髋部骨折是绝经后骨质疏松症(postmenopaus⁃al osteoporosis,PMOP)患者致死、致残的常见原因[1]。全髋骨密度(total hip bone...
placebo-controlled, double-blind, randomized phase 2a clinical trial with denosumab, a receptor activator of nuclear factor-κB ligand inhibitor, evaluating the effects on structure modification in erosive hand OA. Patients were randomized to
Study on the correlation factors of total hip bone density change in postmenopausal osteoporosis patients treated with RANKL inhibitor desumab 在线阅读 下载PDF 引用 收藏 分享 摘要 髋部骨折是绝经后骨质疏松症(postmenopaus⁃al osteoporosis,PMOP)患者致死、致残的常见原因[1]。全髋骨密度(total hip bone...
1 Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw* Longwei Hu1, Liqun Xu2# 1College of Stomatology, School of Medicine, Shanghai Jiao Tong University, Shanghai 2Department of Oral and Maxillofacial Surgery, The Ninth People’s Hospital, Shanghai Jiao Tong University School of ...
Denosumab is the first RANKL inhibitor approved in several countries for the treatment of postmenopausal osteoporosis. These approvals were based on phase 3 clinical trials that evaluated the efficacy (including fracture outcomes) and safety of subcutaneous denosumab administered at 60 mg every 6 months...
In certain aspects, the composition is based on a polypeptide which includes the leading 215 amino acids of the human osteoprotegerin followed by the Fc portion of the human IgG1 protein. Pharmaceutical formulations are provided that are suitable for administering the pharmaceutical composition into ...
官网链接:https://www.medchemexpress.cn/Targets/rankl-rank/effect/inhibitor.html RANKL/RANK抑制剂 MCE 站:RANKL/RANK 品牌:MedChemExpress (MCE) 相关产品:Boldine | 波尔定|Narlumosbart|Amakusamine 热销产品:Piclamilast|Manool|MI-2-2|Artemisic acid|Cytidine 5'-monophosphate|Nicorandil|Deflazacort|Cres...
引起药物性颌骨坏死的主要两大类药物包括双磷酸盐及RANKL抑制剂。RANKL抑制剂地诺塞麦是一种完全人化单克隆抗体,临床上主要用于预防实体肿瘤发生骨转移患者骨相关事件的发生以及用于增加骨质疏松患者的骨密度。本文就地诺塞麦的作用机制、临床应用、副作用,与双磷酸盐比较